632 related articles for article (PubMed ID: 25592339)
21. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
22. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
23. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
24. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
Erfan G; Puig S; Carrera C; Arance A; Gaba L; Victoria I; Garcia-Herrera A; Alos L; Malvehy J
Acta Derm Venereol; 2017 Feb; 97(2):258-260. PubMed ID: 27353949
[No Abstract] [Full Text] [Related]
25. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
26. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
Britten CD
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1395-409. PubMed ID: 23443307
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapy in melanoma.
Kudchadkar RR; Smalley KS; Glass LF; Trimble JS; Sondak VK
Clin Dermatol; 2013; 31(2):200-8. PubMed ID: 23438383
[TBL] [Abstract][Full Text] [Related]
28. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
29. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
[TBL] [Abstract][Full Text] [Related]
30. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK
Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029
[TBL] [Abstract][Full Text] [Related]
31. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
32. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
33. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
34. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
35. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
[TBL] [Abstract][Full Text] [Related]
36. The role of the PI3K-AKT pathway in melanoma.
Davies MA
Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
[TBL] [Abstract][Full Text] [Related]
37. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous toxicities of RAF inhibitors.
Anforth R; Fernandez-Peñas P; Long GV
Lancet Oncol; 2013 Jan; 14(1):e11-8. PubMed ID: 23276366
[TBL] [Abstract][Full Text] [Related]
39. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
40. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
